Combination drug therapy for advanced bile duct cancer with FGFR2 change
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of three drugs (pemigatinib, atezolizumab, and bevacizumab) for people with advanced bile duct cancer that has a specific genetic change called FGFR2 fusion. The goal is to see if this combination can shrink or control the cancer when standard treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced or spread bile duct cancer that cannot be removed by surgery.
- Your tumor has a specific genetic change called FGFR2 fusion or rearrangement.
- You have tried or cannot tolerate standard first-line treatment, like gemcitabine-based therapy.
- You are in generally good health (able to do daily activities, with an Eastern Cooperative Oncology Group performance status of 0 or 1).
- You have adequate liver, kidney, and blood cell function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a combination of lenvatinib, an immunotherapy drug (tislelizumab), and chemotherapy (gemcitabine plus cisplatin) for advanced bile duct cancer that cannot be removed with surgery. It aims to see whether this treatment can shrink tumors and improve outcomes, especially for people who have not yet had immunotherapy.
This study tests a new oral medication (tinengotinib) against standard chemotherapy for people with advanced bile duct cancer that has a specific gene change (FGFR2). Doctors want to see if this drug can help shrink or slow the cancer better than current treatments.
This study tests a combination of two chemotherapy drugs (gemcitabine and cisplatin) with an immunotherapy drug (durvalumab), alternating with a targeted therapy (pemigatinib) for people with advanced biliary tract cancer that has an FGFR2 gene change. The goal is to see if this treatment sequence helps control the cancer.
This study tests a combination of two medications—pemigatinib and durvalumab—for people with advanced bile duct or gallbladder cancer that has stopped responding to prior treatment and has a specific genetic change (FGFR2 fusion). The goal is to see if this combination can shrink or control the cancer better.
This trial tests a combination of two drugs, pemigatinib and durvalumab, in people with a certain type of advanced bile duct cancer that has a specific genetic change (FGFR2 fusion or rearrangement). The goal is to see if this combination can help when standard treatments have stopped working.
This trial tests a pill called pemigatinib for people with bile duct cancer that has spread and has a specific gene change (FGFR2 fusion or rearrangement). It may slow or stop tumor growth. The study is for those whose cancer has progressed after at least one prior treatment.
Hear when a new Advanced Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.